Clinical trials: Patients With Chemotherapy-Induced Thrombocytopenia
Thrombocytopaenia
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or…
- Trial name
- NCT01147809
- Testing
- Eltrombopag olamine
- Where
- 86 sites in United States, Belgium and 11 more
- Volunteers
- 130 people
- Sponsor
- GlaxoSmithKline
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy
This phase II trial studies how well romiplostim works in increasing low platelet counts in patients with multiple myeloma receiving chemotherapy. Romiplostim may cause the body to make platelets after chemotherapy
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01676961
- Testing
- romiplostim
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Patients With Chemotherapy-Induced Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
- Trial name
- NCT07286032
- Testing
- Hetrombopag Olamine
- Where
- 51 sites in United States, Bulgaria and 9 more
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Thrombocytopenia Chemotherapy Induced
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
This study aims to evaluate the efficacy and safety of Romiplostim N01 for Injection administered as secondary prophylaxis in breast cancer patients with chemotherapy-induced thrombocytopenia (CIT).
- Trial name
- NCT07771881
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Thrombocytopenia
High-dose Use of rhTPO in CIT Patients
The research studies the safety and efficacy of high-dose recombinant human TPO in solid tumor patients with moderate or severe thrombocytopenia induced by chemotherapy.
- Trial name
- HUrhTPOCITP (NCT03633019)
- Testing
- rhTPO
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chemotherapy-induced Thrombocytopenia (CIT)
A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Preliminary Efficacy and Pharmacokinetics of SCB-219M in the patients with chemotherapy-induced thrombocytopenia (CIT)
- Trial name
- NCT05426369
- Testing
- Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Thrombocytopenia
- Trial name
- NCT00003619
- Testing
- filgrastim, vitamin E, busulfan
- Where
- 2 sites in United States
- Sponsor
- Drexel University College of Medicine
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of lymphomas measured by the ability to administer on-time, full-dose chemotherapy.
- Trial name
- NCT03343847
- Testing
- Romiplostim
- Sponsor
- Amgen
Advanced Epithelial Ovarian Cancer
Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer
The aim of the current study is to compare weekly versus three-week collective of carboplatin/paclitaxel in advanced epithelial ovarian cancer.
- Trial name
- NCT05963334
- Testing
- Carboplatin/paclitaxel
- Where
- Egypt
- Volunteers
- 49 people
- Sponsor
- Cairo University
Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
This is a prospective, randomized, open-label, active-controlled study to evaluate the efficacy and safety of Romiplostim N01 plus all-trans retinoic acid (ATRA) compared with Romiplostim N01 alone in adults with persistent…
- Conditions
- Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer
- Trial name
- N01-A-PICIT-GT (NCT07586826)
- Testing
- Romiplostim N01, All-trans retinoic acid
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University People's Hospital
Chemotherapy-induced Thrombocytopenia
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy
- Trial name
- NCT03937154
- Testing
- Romiplostim
- Where
- 34 sites in United States, Argentina and 8 more
- Volunteers
- 145 people
- Sponsor
- Amgen
Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use
Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma
This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma
- Conditions
- Thrombocytopenia, Cytarabine Causing Adverse Effects in Therapeutic Use, Lymphoma
- Trial name
- NCT04797182
- Testing
- avatrombopag
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Chemotherapy-Induced Thrombocytopenia
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two…
- Trial name
- NCT01345214
- Testing
- ONO-7746
- Where
- 14 sites in United States, Russia and 1 more
- Volunteers
- 17 people
- Sponsor
- Ono Pharma USA Inc
Ovarian Cancer
Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines
To evaluate the safety of secondary chemotherapy induced thrombocytopenia (reduction in platelets which leads to bleeding) prophylaxis with romiplostim in ovarian cancer subjects receiving myelosuppressive (blood cell damaging)…
- Trial name
- TRACEII (NCT03622931)
- Testing
- Standard chemotherapy, Romiplostim
- Where
- 13 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Solid Tumor
A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia
The purpose of this study is evaluate the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with solid tumor .
- Trial name
- NCT02093325
- Testing
- Eltrombopag
- Where
- 3 sites in Taiwan
- Volunteers
- 83 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Myeloid Leukemia, Neutropenia
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT06245746
- Testing
- umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Thrombocytopenia
The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC
Purpose: To evaluate the efficacy and safety of rHuTPO/rHuIL-11 in the treatment for chemotherapy-induced thrombocytopenia in patients with NSCLC receiving gemcitabine and cisplatin or carboplatin chemotherapy.
- Trial name
- NCT02344979
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Chemotherapy-induced Thrombocytopenia
The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies
Chemotherapy is an important treatment strategy for gynecological malignancies, such as ovarian cancer, advanced endometrial cancer, cervical cancer.
- Trial name
- NCT06099925
- Testing
- Hetrombopag
- Volunteers
- 48 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-Hodgkin Lymphoma
Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia
This is a monocentric, prospective phase II trial addressing safety and capability to prevent grade-4 Chemotherapy-induced Thrombocytopenia (CIT) of romiplostim in patients with NHL.
- Trial name
- ProRom (NCT01516619)
- Testing
- Romiplostim
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Andres J. M. Ferreri
Hematological Patients, Bleeding
Administration of Fibrinogen Concentrate for Refractory Bleeding
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia. Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive…
- Conditions
- Hematological Patients, Bleeding, Platelet Refractoriness
- Trial name
- FORMAT (NCT05091684)
- Testing
- Fibrinogen Concentrate Human
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne